Our program utilizes a collaborative, multi-disciplinary team approach—we believe that is the best way to treat you as a whole person and address your health care needs in a comprehensive fashion. In addition to hematology and medical oncology physicians with vast experience in multiple myeloma and related diseases, the team includes skilled nurse practitioners, physician assistants, registered nurses, clinical social workers, dietitians, and pharmacists. The team also includes leading experts from Mount Sinai’s Bone Marrow Transplant Program and Cellular Therapy Service and specialists from other services such as Pathology, Radiology, Immunology, Genomics, Infectious Diseases, Orthopedic Surgery, Cardiology, and Nephrology.   As a patient at Mount Sinai, you have access to the finest doctors in all medical specialties.

Every patient is unique. Based on a thorough assessment of your disease, we will work with you to craft an individualized treatment plan that takes into account your medical history and condition, as well as your lifestyle and personal preferences. And, we will work closely with your referring physician to ensure continuity of your care.

We welcome patients from the local region and across the United States, as well as international patients. We are committed to meeting the individual needs of each patient in an environment of compassion, comfort, and excellence.

Our program is led by Samir Parekh, MD, Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Dr. Parekh is Co-Leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute and a member of the Icahn Genomics Institute. He conducts research on development of individualized, precision-medicine therapies for multiple myeloma and other hematological malignancies.

Dr. Parekh succeeds Sundar Jagannath, MD,  who led the program from 2010 until September 2024. Dr. Jagannath continues to care for patients and he also serves as Network Director, with a focus on expanding multiple myeloma clinical care and research across the Mount Sinai Health System and with other institutional collaborators.

We are an integral part of The Tisch Cancer Institute, which is a National Cancer Institute-Designated Cancer Center. This designation recognizes our standards of excellence and breakthrough accomplishments in research aimed at prevention and cure.

As an academic medical complex, the Mount Sinai Health System is affiliated with the Icahn School of Medicine. We are proud to participate in the education of the next generation of myeloma experts.